Natera Reports Third Quarter 2026 Financial Results
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Revenue $794.0 million, up 34.1% year over year
- ➤2026 revenue guidance raised to $3.005 billion-$3.035 billion
- ➤Oncology tests processed 339,500, up 60.9% year over year
- ➤Net loss narrowed to $59.9 million, or $0.42 per share
- ➤Non-GAAP gross margin increased 137 basis points sequentially
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.
* Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.
Get started
Create a free account to read the full story.